Apnimed Acquires Global Rights to Additional Sleep Apnea Drug Candidate
Apnimed has acquired global rights to develop and commercialize a carbonic anhydrase inhibitor with promising phase 2 results for OSA.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
